|

Pomalidomide Clinical Trials

31 actively recruiting trials across 14 locations

▼ -2 trials since July 2026

Also known as: 4-Aminothalidomide, Actimid, Anyve, CC 4047, CC-4047 +10 more

Pipeline

Phase 1: 5Phase 2: 8Phase 3: 12Phase 1/2: 5

Top Sponsors

  • Regeneron Pharmaceuticals2
  • Qilu Pharmaceutical Co., Ltd.2
  • Pfizer2
  • National Cancer Institute (NCI)2
  • AstraZeneca2

Indications

  • Cancer31
  • Multiple Myeloma15
  • Relapsed or Refractory Multiple Myeloma3
  • Relapsed/ Refractory Multiple Myeloma3
  • Non-hodgkin Lymphoma2

Other8 trials

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Phase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Phase 3
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Phase 2
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
N/A
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Phase 2

Birmingham, Alabama3 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Duarte, California3 trials

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site

Phase 1/2
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

City of Hope National Medical Center

Phase 3
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2

Gilbert, Arizona2 trials

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site

Phase 3
Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Los Alamitos, California2 trials

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Local Institution - 0366

Phase 3
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

GSK Investigational Site

Phase 2

Los Angeles, California2 trials

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Southern California /ID# 272414

Phase 1/2
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

University of California Los Angeles (UCLA)

Phase 3

Atlanta, Georgia2 trials

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Emory University/Winship Cancer Institute

Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Bethesda, Maryland2 trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center

Phase 1
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

National Institutes of Health Clinical Center

Phase 1

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Clovis, California1 trial

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Clovis Community Medical Center

Phase 3

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Denver, Colorado1 trial

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Colorado Blood Cancer Institute

Phase 1

Chicago, Illinois1 trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Boston, Massachusetts1 trial

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 2

Ann Arbor, Michigan1 trial

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

University of Michigan Rogel Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.